Suzhou Huitherapy Biomedical Technology

The leadership team consists of co-founders Tianyi Zhong, who serves as CEO, Jianhao Jiang, the COO, and Lixiang Zhao, the company's CTO. This founding group directs the company's efforts in creating an mRNA drug technology platform with independent intellectual property rights in China.

Healrna's core business revolves around developing nucleic acid therapeutics for a wide range of diseases, including infectious diseases, cancer vaccines, immunotherapy, and metabolic and rare diseases. A significant area of focus for the company is the veterinary market, where it is developing innovative mRNA vaccines for livestock. One of its key projects involves a trivalent mRNA vaccine for porcine rotavirus (PoRV), which aims to protect the pig farming industry and holds public health significance by potentially blocking virus transmission to humans.

The company's primary technological asset is its proprietary drug delivery platform, the Cell Like System (CLS). This system is designed to overcome the challenges of delivering mRNA drugs effectively and is presented as a distinct alternative to the more common Lipid Nano Particle (LNP) delivery systems used by other major mRNA vaccine producers. The CLS technology is derived from the structure of protein-phospholipid layers in biomimetic cell membranes, making it particularly suitable for the targeted delivery of mRNA.

Since its inception, the company has achieved several milestones, including being named a "Unicorn" cultivation enterprise in Suzhou and securing the initial closing of a nearly 100 million yuan Series A financing round in January 2025, led by Guozhong Capital. These funds are intended to accelerate the innovation and development of its pipeline products. Healrna actively participates in industry conferences to showcase its developments, such as its veterinary mRNA vaccine solutions.